Kohno Hitoshi, Igarashi Yutaka, Ozono Keiichi, Ohyama Kenji, Ogawa Masamichi, Osada Hisao, Onigata Kazumichi, Kanzaki Susumu, Seino Yoshiki, Takahashi Hiroaki, Tajima Toshihiro, Tachibana Katsuhiko, Tanaka Hiroyuki, Nishi Yoshikazu, Hasegawa Tomonobu, Fujieda Kenji, Fujita Keinosuke, Horikawa Reiko, Yokoya Susumu, Yorifuji Toru, Tanaka Toshiaki
Department of Pediatrics, Fukuoka Tokushukai Hospital, Fukuoka, Japan ; Igarashi Children's Clinic, Sendai, Japan.
Clin Pediatr Endocrinol. 2012 Apr;21(2):29-34. doi: 10.1297/cpe.21.29. Epub 2012 Mar 24.
Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases.
To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan.
Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight.
Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter.
Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.
